U.S. and South Africa Roll Out Twice-Yearly HIV Prevention Shot Lenacapavir

Lenacapavir – a twice‑yearly injectable HIV prevention drug.

Effectiveness: 99.9% in clinical trials (near‑total protection).

Developer: U.S. company Gilead Sciences.

Announcement: Made by the U.S. Mission to South Africa on 5 June 2026, via @USEmbassySA account.

Partnership: Part of PEPFAR (U.S.‑South Africa bilateral collaboration) and also involves the Global Fund.

Why significant for South Africa: The country has one of the world’s highest HIV burdens; the drug offers a practical alternative to daily pills, which can improve adherence.

Rollout status: South Africa is the first African country to roll out lenacapavir under this partnership.

Public reaction / viral reason: Gained traction in health and diplomatic circles as a major prevention breakthrough; early replies were limited and mixed (some support, some unrelated political comments).

Sequence:

• 5 June 2026 (20:34 GMT) – announcement posted with three official photos.

• Hours after – initial replies (comments on veterans’ issues, tariffs).

• 6 June 2026 – post continues circulating in health‑policy discussions.